Ligand director Jason Aryeh proposes $960K share sale

The notice also lists four earlier sales, dated October 30 through November 4, with gross proceeds reported separately for each.

Available on EDGAR 11/10/2026 - 02:25 PM EST Accepted by SEC EDGAR 11/10/2026 - 02:25 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc. director Jason Aryeh filed notice of a proposed sale of 3,000 shares of Class B common, with an approximate sale date of November 10, 2026. The notice lists an aggregate market value of $960,084.19 for the shares.

Key Figures

Proposed shares to be sold: 3,000 shares Aggregate market value: $960,084.19 Shares sold: 1,209 shares +3 more

6 metrics

Proposed shares to be sold 3,000 shares Class B common

Aggregate market value $960,084.19 Proposed sale

Shares sold 1,209 shares October 30, 2026

Shares sold 202 shares October 30, 2026

Shares sold 700 shares November 2, 2026

Shares sold 282 shares November 4, 2026

Key Terms

Aggregate Market Value, Secondary Market Purchase, Gross Proceeds

3 terms

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Secondary Market Purchase financial

"Nature of Acquisition Transaction: Secondary Market Purchase"

Gross Proceeds financial

"Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares does Jason Aryeh propose to sell?

Director Jason Aryeh reported a proposed sale of 3,000 shares of Class B common, with an approximate sale date of November 10, 2026. The notice lists an aggregate market value of $960,084.19.

What earlier LGND sales did Jason Aryeh report?

The notice lists 1,209 shares sold on October 30, 2026, for gross proceeds of $385,185.47; 202 shares on October 30 for $64,738.00; 700 shares on November 2 for $221,595.09; and 282 shares on November 4 for $90,225.50.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001376960
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INC
SEC File Number	001-33093
Address of Issuer	3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CALIFORNIA 92121
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	Aryeh Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class B common	Wells Fargo Clearing Sevices 1 North Jefferson Avenue St. Louis MO 63103	3000	960084.19	20002986	11/10/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class B common	05/14/2019	Secondary Market Purchase	Secondary Market			3000	05/14/2019	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	10/30/2026	1209	385185.47
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	10/30/2026	202	64738.00
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	11/02/2026	700	221595.09
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	11/04/2026	282	90225.50

144: Remarks and Signature

Remarks	shares were acquired between 05/14/2019 to 07/30/2019.
Date of Notice	11/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jason Aryeh
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)